Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jiannipai (recombinant anti-CD25 antibody) to prevent GVHD after haploidentical or unrelated HSCT in transfusion-dependent thalassemia
ChiCTR2600124426Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of daclizumab in beta thalassemia (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Incidence of grade III–IV acute GVHD within 100 days after HID-HSCT/MUD-HSCT. Started May 2026; status: recruiting.
02
Drugs
daclizumab
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on ChiCTR2600124426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124426.